Curza is a small molecule therapeutics R&D company founded in 2013, with a primary focus on developing new drugs to combat antibiotic resistance. With the slogan "Small molecule therapeutics R&D company focused on developing new drugs to combat antibiotic resistance," Curza has positioned itself as a major player in the biotechnology and health care industries.
Curza has made significant strides in the field, having developed a novel class of antibiotics that demonstrate activity and selectivity against Gram-negative pathogens. This innovation has garnered attention and investment, with the company securing a noteworthy $5.25M Venture Round investment on 25 July 2019, with the Repair Impact Fund as the contributing investor.
As the threat of antibiotic resistance continues to rise, Curza's dedication to pioneering new therapeutic solutions positions the company as a key player in addressing this critical global health concern. With its innovative approach and financial backing, Curza stands poised to make a significant impact in the fight against antibiotic resistance.
